Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Inclusion Criteria: * Patients with type 1 or type 2 diabetes mellitus and HbA1c of ≤10% at Screening * BCVA score between 23 and 65 letters, inclusive, using ETDRS visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/50 to 20/320), at screening and baseline * DME involving the center of the macula, with central subfield retinal thickness (measured from RPE to ILM inclusively) of ≥ 320 µm on SD-OCT Exclusion Criteria: * High risk or advanced proliferative diabetic retinopathy in the study eye as per reading Center * Active intraocular or periocular infection or active intraocular inflammation in the study eye * Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) \> 25 millimeters mercury (mmHg) * Previous treatment with any anti-VEGF drugs or investigational drugs in the study eye in the last 3 months prior randomization * Stroke or myocardial infarction during the 6-month period prior to baseline * Uncontrolled blood pressure defined as a systolic value ≥160 mmHg or diastolic value ≥100 mmHg Other protocol-specified inclusion/exclusion criteria may apply